doi:10.3969/j.issn.1004-583X.2026.06.015

Abstract

CLC Number:

R574.62

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.06.015

https://www.lchc.cn/EN/Y2026/V41/I6/568

References 33

[1]	Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778.doi: 10.1016/S0140-6736(17)32448-0.
[2]	杨红, 钱家鸣. 《中国溃疡性结肠炎诊治指南(2023年·西安)》解读[J]. Beijing Med, 2024, 46(11): 999-1002. doi:10.15932/j.0253-9713.2024.11.017.
[3]	Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline update: Ulcerative colitis in adults[J]. Am J Gastroenterol, 2025, 120(6): 1187-1224.doi: 10.14309/ajg.0000000000003463. pmid: 40701556
[4]	Acevedo D, Salvador MP, Girbes J, et al. Fecal calprotectin: A comparison of two commercial enzymoimmunoassays and study of fecal extract stability at room temperature[J]. J Clin Med Res, 2018, 10(5): 396.doi: 10.14740/jocmr3275e. pmid: 29581802
[5]	Li T, Jing H, Gao X, et al. Identification of key genes as diagnostic biomarkers for IBD using bioinformatics and machine learning[J]. J Transl Med, 2025, 23(1): 738. doi:10.1186/s12967-025-06531-1. pmid: 40611294
[6]	Barczyk M, Carracedo S, Gullberg D. Integrins[J]. Cell and Tissue Research, 2009, 339(1): 269-280. doi:10.1007/s00441-009-0834-6.
[7]	Yu Y, Chen S, Lu GF, et al. Alphavbeta6 is required in maintaining the intestinal epithelial barrier function[J]. Cell Biol Int, 2014, 38(6): 777-781. doi:10.1002/cbin.10258. pmid: 24677750
[8]	Koivisto L, Bi J, Häkkinen L, et al. Integrin αvβ6: Structure, function and role in health and disease[J]. Int J Biochem Cell Biol, 2018, 99: 186-196.doi: 10.1016/j.biocel.2018.04.013. pmid: 29678785
[9]	Roth D, Düll MM, Horst LJ, et al. Integrin αVβ6 as autoantigen and driver of epithelial remodeling in IBD[J]. J Crohns Colitis, 2025, 19(2): jjae131. doi:10.1093/ecco-jcc/jjae131.
[10]	Pertsinidou E, Salomon B, Bergemalm D, et al. Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype[J]. Crohns Colitis, 2025, 19(5):jjaf062. doi:10.1093/ecco-jcc/jjaf062.
[11]	Nihira H, Shiokawa M, Izawa K, et al. Anti-integrin αvβ6 antibody as a diagnostic marker for pediatric patients with ulcerative colitis[J]. Gastroenterology, 2022, 163(4): 1094-1097.e14. doi:10.1053/j.gastro.2022.06.026. pmid: 35709831
[12]	Nakanishi R, Kuwada T, Shiokawa M, et al. Anti-integrin αvβ6 antibodies predict pouchitis after IPAA[J]. Inflamm Bowel Dis, 2025, 31(3): 777-785. doi:10.1093/ibd/izae263. pmid: 39657162
[13]	Ishikawa Y, Yoshida H, Yoshifuji H, et al. Anti-integrin αvβ6 antibody in Takayasu arteritis patients[J]. Front Immunol, 2024, 15: 1387516. doi:10.3389/fimmu.2024.1387516.
[14]	Livanos AE, Dunn A, Fischer J, et al. Autoantibodies against endothelial protein C receptor and integrin αvβ6 predict the development of ulcerative colitis[J]. Gastroenterology, 2024, 167(1): 238-250.e8. doi:10.1053/j.gastro.2024.04.023.
[15]	Yamamoto S, Kuwada T, Shiokawa M, et al. Anti-integrin αvβ6 antibody titer as a predictive biomarker of future treatment escalation[J]. Gastro Hep Adv, 2025, 4(3): 100582. doi:10.1016/j.gastha.2024.10.022.
[16]	Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an anti-integrin αvβ6 autoantibody in patients with ulcerative colitis[J]. Gastroenterology, 2021, 160(7): 2383-2394.e21. doi:10.1053/j.gastro.2021.02.019. pmid: 33582126
[17]	Chen H, Chen L, Wang X, et al. Transgenic overexpression of ITGB6 exacerbates DSS-induced colitis in mice[J]. J Cell Mol Med, 2021, 25(5): 2679-2690. doi: 10.1111/jcmm.v25.5 URL
[18]	Sun Q, Lu Z, Ma L, et al. Integrin β6 deficiency protects mice from experimental colitis and colitis-associated carcinoma[J]. Front Oncol, 2023, 13: 1190229. doi:10.3389/fonc.2023.1190229.
[19]	Marafini I, Laudisi F, Salvatori S, et al. Diagnostic value of anti-integrin αvβ6 antibodies in ulcerative colitis[J]. Dig Liver Dis, 2024, 56(1): 55-60. doi:10.1016/j.dld.2023.06.024.
[20]	Livanos AE, Dunn A, Fischer J, et al. Anti-integrin αvβ6 autoantibodies antedate ulcerative colitis[J]. Gastroenterology, 2023, 164(4): 619-629. doi:10.1053/j.gastro.2022.12.042.
[21]	Okabe M, Yamamoto S, Shiokawa M, et al. Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis[J]. J Gastroenterol, 2025, 60(1): 86-95. doi:10.1007/s00535-024-02176-x.
[22]	Bez P, Scapolan M, Ribaldone DG, et al. Antibodies against integrin αvβ6 have high diagnostic accuracy for ulcerative colitis[J]. Front Immunol, 2025, 16: 1641329. doi: 10.3389/fimmu.2025.1641329 URL
[23]	Nisar M, Awan AR, Ahmad A, et al. Diagnostic accuracy of anti-integrin αvβ6 in ulcerative colitis: A meta-analysis[J]. J Gastroenterol, 2025: 1-15.
[24]	Pertsinidou E, Salomon B, Bergemalm D, et al. Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype[J]. J Crohns Colitis, 2025, 19(5): jjaf062. doi:10.1093/ecco-jcc/jjaf062.
[25]	Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for IBD[J]. Am J Gastroenterol, 2007, 102(4): 803-813. doi: 10.1111/ajg.2007.102.issue-4 URL
[26]	Kapel N, Ouni H, Benahmed NA, et al. Fecal calprotectin for diagnosis and management of inflammatory bowel diseases[J]. Clin Transl Gastroenterol, 2023, 14(9): e00617. doi: 10.14309/ctg.0000000000000617 URL
[27]	Stevens TW, Gecse K, Turner JR, et al. Diagnostic accuracy of fecal calprotectin concentration in ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2021, 19(11): 2333-2342. doi: 10.1016/j.cgh.2020.08.019 URL
[28]	Sasidharan S, Sasson AN, Shannon KM, et al. Fecal calprotectin predicts need for rescue therapy in severe colitis[J]. Inflamm Bowel Dis, 2022, 28(12): 1833-1837. doi: 10.1093/ibd/izac011 pmid: 35134899
[29]	Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS using fecal and blood markers[J]. Inflamm Bowel Dis, 2008, 14(1): 32-39. doi:10.1002/ibd.20275. pmid: 17924558
[30]	Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease[J]. Digestion, 2023, 104(1): 30-41. doi: 10.1159/000527846 URL
[31]	Smith J, Doe A, Chen L, et al. Inflammatory bowel disease and pANCA: A systematic review[J]. J Gastroenterol Hepatol, 2023, 15(4): 123-135. doi:10.1002/jgh.12345.
[32]	Mendieta-Escalante EA, Faber KN, Dijkstra G. Current and emerging autoantibodies in ulcerative colitis[J]. Eur J Immunol, 2025, 55(8): e51721. doi: 10.1002/eji.v55.8 URL
[33]	Yokode M, Shiokawa M, Kawakami H, et al. Anti-integrin αvβ6 autoantibodies in immune checkpoint inhibitor-induced colitis[J]. Br J Cancer, 2024, 130(9): 1552-1560. doi:10.1038/s41416-024-02647-1.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 33

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Xiaotian, Huo Lijuan. Predictive value of serum total bilirubin, neutrophil-to-total bilirubin ratio in evaluating the condition of ulcerative colitis [J]. Clinical Focus, 2024, 39(7): 603-611.
[2]	Zhang Xiumin, Zhao Changdong, Li Xue, Lu Xuefeng, Liu Weizhong, Wang Shufang. Relationship between indoleamine 2, 3-dioxygenase and peripheral blood CD4 + in patients with ulcerative colitis [J]. Clinical Focus, 2021, 36(8): 696-698.
[3]	Song Yiran, Liang Xiaonan, Li Chenyang, Zhang Xiaolan. Interpretation on Chinese Expert Consensus of Irritable Bowel Syndrome in 2020 [J]. Clinical Focus, 2021, 36(7): 628-631.
[4]	. [J]. Clinical Focus, 2021, 36(5): 467-470.
[5]	. [J]. Clinical Focus, 2015, 30(9): 1056-1059.
[6]	ZHENG Xiu-li;FU Xue-song;WANG Yu-gang;ZHANG Yan-hua;ZHAO Xia;LI Hong-yin. Effect of otilonium bromide combined with probiotics for diarrhea-predominant irritable bowel syndrome [J]. Clinical Focus, 2014, 29(10): 1168-1170.
[7]	WU Xiao-lei;ZHU Fang-li;LV Xiao-min;SONG Jia;ZHANG Xiao-lan. Association of CYP27B1 gene promoter polymorphism with ulcerative colitis [J]. CLINICAL FOCUS, 2013, 28(11): 1249-1251.
[8]	LIU Lei;ZHANG Hong;NIU Guo-chao;WU Hui;LI Hui;ZHANG Xiao-lan. Effect of human umbilical cord mesenchymal stem cells on cycloxygenase-2 expression in dextran sodium sulfate-induced chronic colitis [J]. CLINICAL FOCUS, 2013, 28(7): 763-0.
[9]	. [J]. Clinical Focus, 2013, 28(4): 464-467.
[10]	XU Guang-hui;QIU Min-jie;LING Guo-min;LI Hui-min;LIU Bin;WANG Ze-yan. Relation between melanosis coli and expression of oncogene as well as its clinical significance [J]. CLINICAL FOCUS, 2013, 28(3): 294-297.
[11]	. [J]. CLINICAL FOCUS, 2013, 28(3): 318-319.
[12]	LV Fei;LU Guang-xin;DU Yong. Effects of compound glycyrrhizin on serum expression of interleukin 4, interleukin 7 level in experimental ulcerative colitis of rats [J]. Clinical Focus, 2013, 28(2): 178-180.
[13]	. [J]. Clinical Focus, 2012, 27(23): 2109-2112.
[14]	. [J]. Clinical Focus, 2012, 27(17): 1534-1535.
[15]	. [J]. Clinical Focus, 2012, 27(13): 1147-1149.